This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary Study Objective: to evaluate GH secretory function and conduct Dose Optimization (DO) Study in adults with Prader-Willi Syndrome followed at three or four United States clinical centers. Secondary Study Objective: to evaluate efficacy, safety and dose optimization in a one-year open-label surveillance trial of adult growth hormone (GH) deficient Prader Willi Syndrome (PWS) patients treated with Genotropin- administered via the Mini-quick- device using the KIMS DO dosing schedule for older adults as defined in the referenced protocol. Primary Study Objective to evaluate GH secretory function and conduct Dose Optimization (DO) Study in adults with Prader-Willi Syndrome followed at three or four United States clinical centers. Secondary Study Objective: to evaluate efficacy, safety and dose optimization in a one-year open-label surveillance trial of adult growth hormone (GH) deficient Prader Willi Syndrome (PWS) patients treated with Genotropin- administered via the Mini-quick- device using the KIMS DO dosing schedule for older adults as defined in the referenced protocol.
Showing the most recent 10 out of 1085 publications